Michele Voeltz, MD
Interventional Cardiology · Atlanta, GANPI 1801910393
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Abiomed accounts for 61.5% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2022 at $9,388 and has fallen 74.3% since, to $2,408 in 2025.
Across 177 payments — averaging $149.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$16K
- Philips North America LLC$2K
- Boston Scientific$2K
- Medtronic$2K
- W. L. Gore & Associates, Inc.$929
- Shockwave Medical, Inc$533
- plus $3K from 34 others
Across 1 payment — averaging $1164.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$1K
What the payments were for
- Consulting fees$3,38013%
- Speaking & faculty fees$14,70056%
- Travel & lodging$2,64610%
- Food & beverage$5,71122%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 15 | $16,255 |
| Philips North America LLC | 2 | $1,955 |
| Boston Scientific | 22 | $1,842 |
| Medtronic | 6 | $1,587 |
| W. L. Gore & Associates, Inc. | 13 | $929 |
| Shockwave Medical, Inc | 5 | $533 |
| Abbott | 8 | $404 |
| Biotronik Inc. | 3 | $322 |
| Novartis | 14 | $290 |
| Amgen | 16 | $278 |
| Penumbra, Inc. | 2 | $252 |
| Inari Medical, Inc. | 1 | $182 |
| Pfizer | 8 | $156 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $124 |
| AstraZeneca | 7 | $120 |
| Potrero Medical, Inc. | 1 | $116 |
| Cvrx, Inc. | 3 | $105 |
| Angiodynamics, Inc. | 3 | $91 |
| Johnson & Johnson | 4 | $63 |
| Merck | 3 | $60 |
| E.r. Squibb & Sons, L.L.C. | 3 | $56 |
| Siemens Medical Solutions USA, Inc. | 1 | $51 |
| Cardinal Health 200 LLC | 2 | $50 |
| Boehringer Ingelheim | 3 | $49 |
| Atricure, Inc. | 1 | $49 |
| Sanofi-aventis U.S. LLC | 2 | $48 |
| Cardiva Medical, Inc. | 2 | $47 |
| Bayer | 2 | $46 |
| Chiesi USA, Inc. | 3 | $45 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Actelion Pharmaceuticals US, Inc. | 2 | $38 |
| Novo Nordisk | 2 | $37 |
| Scpharmaceuticals Inc. | 1 | $35 |
| Heartflow, Inc. | 1 | $35 |
| Terumo Medical Corporation | 2 | $35 |
| Daiichi Sankyo Inc. | 1 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| B. Braun Interventional Systems Inc. | 1 | $22 |
| Kestra Medical Technology Services, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$16,142
- (9520) IGT Devices Undivided$1,880
- GENERAL - THERAPIES$1,195
- GORE CARDIOFORM Septal Occluder$525
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$314
- Indigo System$252
- FLOWTRIEVER CATHETER, S$182
- CT THROMBECTOMY SYSTEM KIT$182
- Vascular Lithotripsy$169
- AMPLATZER AMULET$167
- Rivacor 7 DR-T$150
- Acticor 7 VR-T DX$150
- PK Papyrus$150
- Orsiro Mission$150
- BioMonitor$150
- PORTICO$128
- CARDIOFORM Septal Occluder$122
How this compares
$26,437 in reported general payments places this provider in the 75th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 96 | $110,497 |
| BrilintaTicagrelor | 14 | $6,917 |
| Atorvastatin Calcium | 160 | $1,271 |
| Spironolactone-HctzSpironolact/Hydrochlorothiazid | 24 | $1,166 |
| Nifedipine ErNifedipine | 28 | $1,027 |
| Metoprolol Succinate | 119 | $1,003 |
| Ranolazine ErRanolazine | 17 | $812 |
| Losartan Potassium | 100 | $764 |
| Rosuvastatin Calcium | 66 | $690 |
| Carvedilol | 121 | $637 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 12 | $576 |
| Amlodipine Besylate | 80 | $388 |
| Hydralazine Hcl | 20 | $351 |
| Chlorthalidone | 22 | $290 |
| Lisinopril | 56 | $266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $156 | $110,49796 claims |
| AstraZenecaBrilinta | $120 | $6,91714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Atlanta
- William NicholsonAtlanta$1000K
- David KandzariAtlanta$982K
- Pradeep YadavAtlanta$656K
- Adam GreenbaumAtlanta$238K
- Wissam JaberAtlanta$222K
- Katherine KunkelAtlanta$189K
- James StewartAtlanta$174K
- Pratik SandesaraAtlanta$165K
- Chandanreddy DevireddyAtlanta$121K
- Prashant KaulAtlanta$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.